Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Evotec SE

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

ALL CLOSING REQUIREMENTS SATISFIED FOLLOWING ANNOUNCEMENT OF A NON-BINDING TERM-SHEET AGREEMENT IN JULY AND SIGNING OF CONTRACT IN NOVEMBER AGREEMENT INCLUDES APPROXIMATELY US$ 350 M IN CASH FOR JUST - EVOTEC BIOLOGICS MANUFACTURING SITE IN TOULOUSE AND UPFRONT TECHNOLOGY LICENSE FEES TO EVOTEC'S CONTINUOUS MANUFACTURING PLATFORM IN ADDITION, EVOTEC ELIGIBLE FOR LICENSE FEES, AND DEVELOPMENT REVENUES INCLUDING SUCCESS-BASED MILESTONES ADDING UP TO MORE THAN US$ 300 M OVER THE COMING YEARS,REPLACING EXISTING CONTRACTUAL COMMITMENTS TRANSACTION COVERING ROYALTIES ON A PORTFOLIO OFUP TO TEN BIOSIMILARS IN TECHNICAL AND EARLY DEVELOPMENT TARGETINGMORE THAN US$ 90 BN OF ORIGINATOR NET SALES SALE IMMEDIATELY EARNINGS ACCRETIVE, IMPROVING EVOTEC'S SHORT, MID AND LONG-TERM REVENUE MIX, PROFIT MARGINS, AND CAPITAL EFFICIENCY HAMBURG, DE / ACCESS NEWSWIRE / DECEMBER 8, 2025 / EVOTEC SE (FRANKFURT STOCK EXCHANGE:EVT, SDAX/TECDAX, PRIME STANDARD, ISIN: DE0005664809, WKN 566480; NASDAQ:EVO) TODAY ANNOUNCED THE CLOSING OF ITS PREVIOUSLY REPORTED SALE OF THE JUST - EVOTEC BIOLOGICS TOULOUSE SITE PLUS AN INDEFINITE TECHNOLOGY LICENSE TO EVOTEC'S CONTINUOUS MANUFACTURING PLATFORM TECHNOLOGY TO SANDOZ AG (SIX:SDZ / OTCQX:SDZNY), EFFECTIVE 05 DECEMBER 2025. IN TOTAL, POTENTIAL PAYMENTS MAY EXCEED US$ 650 M PLUS ROYALTIES ON A PORTFOLIO OF UP TO 10 BIOSIMILAR MOLECULES, OF WHICH SIX HAVE AN ORIGINATOR NET SALES VALUE OF US$ 90 BN.

EVOTEC CLOSES SALE OF JUST - EVOTEC BIOLOGICS' TOULOUSE SITE TO SANDOZ

PHASE 2 CLINICAL TRIAL INITIATED TO EVALUATE SEMA3A MAB AS POTENTIAL TREATMENT FOR ALPORT SYNDROME MILESTONE PAYMENT TO EVOTEC EXPECTED UPON FIRST DOSING OF FIRST STUDY PARTICIPANT IN EARLY 2026 HAMBURG, DE / ACCESS NEWSWIRE / DECEMBER 4, 2025 / EVOTEC SE (FRANKFURT STOCK EXCHANGE:EVT, SDAX/TECDAX, PRIME STANDARD, ISIN: DE0005664809, WKN 566480; NASDAQ:EVO) TODAY ANNOUNCED THAT ITS PARTNER BAYER AG HAS INITIATED A PHASE 2 CLINICAL STUDY OF A KIDNEY DISEASE PROGRAM ORIGINATING FROM THE MULTI-TARGET RESEARCH COLLABORATION BETWEEN EVOTEC AND BAYER IN KIDNEY DISEASES. UNDER THE TERMS OF THE COLLABORATION AGREEMENT, EVOTEC IS ELIGIBLE TO RECEIVE A MILESTONE PAYMENT UPON FIRST PATIENT DOSING, WHICH IS EXPECTED IN EARLY 2026.

EVOTEC-PARTNER BAYER STARTS PHASE 2 STUDY FOR TREATMENT OF PATIENTS WITH ALPORT SYNDROME

LENEXA, KS, NOV. 13, 2025 (GLOBE NEWSWIRE) -- DIGITAL ALLY, INC. (NASDAQ: DGLY)(THE COMPANY),A LEADING PROVIDER OF VIDEO SOLUTIONS WHICH DEVELOPS, MANUFACTURES, AND MARKETS ADVANCED VIDEO RECORDING PRODUCTS AND OTHER CRITICAL SAFETY PRODUCTS FOR LAW ENFORCEMENT, EMERGENCY MANAGEMENT, FLEET SAFETY, AND EVENT SECURITY, IS FORGING AHEAD WITH CUTTING-EDGE INNOVATIONS AND STRONG LEADERSHIP AIMED AT RESHAPING THE FUTURE OF SECURITY AND EFFICIENCY IN VIDEO TECHNOLOGY SYSTEMS.

DIGITAL ALLY ADDS NEW IN-CAR CAMERA SOLUTION EVO-CORE TO ITS ECOSYSTEM OF VIDEO PRODUCTS

MILESTONE PAYMENT REFLECTS CONTINUED PROGRESS UNDER STRATEGIC RESEARCH COLLABORATION ADDRESSING HIGH-NEED PATIENT POPULATIONS FDA CLEARANCE OF IND APPLICATION TRIGGERED A US$ 5 M MILESTONE PAYMENT TO EVOTEC HAMBURG, DE / ACCESS NEWSWIRE / NOVEMBER 12, 2025 / EVOTEC SE (FRANKFURT STOCK EXCHANGE: EVT, SDAX/TECDAX, PRIME STANDARD, ISIN: DE0005664809, WKN 566480; NASDAQ:EVO) TODAY ANNOUNCED THAT IT HAS RECEIVED A US$ 5 M MILESTONE PAYMENT FROM BRISTOL MYERS SQUIBB, FOLLOWING THE ACCEPTANCE OF AN INVESTIGATIONAL NEW DRUG ("IND") APPLICATION BY THE U.S. FOOD AND DRUG ADMINISTRATION ("FDA") IN THEIR STRATEGIC PROTEIN DEGRADATION PARTNERSHIP. THE DRUG CANDIDATE, A CEREBLON E3 LIGASE MODULATOR ("CELMOD") WAS DEVELOPED UNDER THE COLLABORATION, AND A PHASE 1 CLINICAL TRIAL IS EXPECTED TO BEGIN IN 2026.

EVOTEC RECEIVES MILESTONE PAYMENT FROM BRISTOL MYERS SQUIBB FOLLOWING IND ACCEPTANCE IN STRATEGIC PROTEIN DEGRADATION PARTNERSHIP

GROUP REVENUES OF  535.1 M ((7.1)%); DISCOVERY & PRECLINICAL DEVELOPMENT SEGMENT ("D&PD", (12.3)%) STILL SEES SOFT DEMAND;JUST - EVOTEC BIOLOGICS ("JEB"; +11.3%) ABOVE-EXPECTATION; FURTHER ACCELERATING GROWTH ON NON-SANDOZ / NON-DOD BUSINESS STRONG SCIENTIFIC ADVANCEMENTS OF CO-DEVELOPED ASSET PIPELINE: EXPECTING UP TO FOUR MOLECULES IN CLINICAL PHASE II IN NEXT SIX TO NINE MONTHS SIGNING OF LANDMARK INDUSTRY TRANSACTION WITH SANDOZ ON 04 NOVEMBER, RESULTING IN PAYMENTS POTENTIALLY OVER US$ 650 M PLUS ROYALTIES ON PORTFOLIO OF UP TO 10 BIOSIMILAR MOLECULES 2025 GUIDANCE AND 2028 OUTLOOK CONFIRMED HAMBURG, DE / ACCESS NEWSWIRE / NOVEMBER 5, 2025 / EVOTEC SE (FRANKFURT STOCK EXCHANGE: EVT, SDAX/TECDAX, PRIME STANDARD, ISIN: DE0005664809, WKN 566480; NASDAQ: EVO) TODAY ANNOUNCED ITS BUSINESS UPDATE FOR 9M 2025, ILLUSTRATING THE ONGOING SYSTEMATIC EXECUTION OF ITS STRATEGY. IN THE D&PD SEGMENT, THE MARKET FOR EARLY DRUG DISCOVERY SERVICES REMAINED SOFT, WHILE STRATEGIC PARTNERSHIPS ARE ON TRACK AND EVOTEC RECORDS STRONG PROGRESS IN ITS PARTNERED ASSET PIPELINE.

EVOTEC SE REPORTS 9M 2025 RESULTS: CONTINUED STRONG EXECUTION ON STRATEGIC PRIORITIES

TRANSACTION SHOWCASES EVOTEC'S UNIQUE CAPABILITY ENABLING CUSTOMERS TO PRODUCE BIOLOGICS FASTER AND AT LOWER COSTS THROUGH ITS CONTINUOUS MANUFACTURING TECHNOLOGY ACCELERATED IMPLEMENTATION OF STRATEGY THROUGH BETTER MONETIZATION OF TECHNOLOGY AND TRANSITIONING TO AN ASSET-LIGHTER BUSINESS MODEL AGREEMENT INCLUDES APPROXIMATELY US$ 350 M IN CASH FOR JUST - EVOTEC BIOLOGICS MANUFACTURING SITE IN TOULOUSE AND UPFRONT TECHNOLOGY LICENSE FEES TO EVOTEC'S CONTINUOUS MANUFACTURING PLATFORM IN ADDITION, EVOTEC ELIGIBLE FOR LICENSE FEES, AND DEVELOPMENT REVENUES INCLUDING SUCCESS-BASED MILESTONES ADDING UP TO MORE THAN US$ 300 M OVER THE COMING YEARS, REPLACING EXISTING CONTRACTUAL COMMITMENTS TRANSACTION COVERING ROYALTIES ON A PORTFOLIO OF UP TO TEN BIOSIMILARS IN TECHNICAL AND EARLY DEVELOPMENT TARGETING MORE THAN US$ 90 BN OF ORIGINATOR NET SALES SALE IMMEDIATELY EARNINGS ACCRETIVE, IMPROVING EVOTEC'S SHORT, MID AND LONG-TERM REVENUE MIX, PROFIT MARGINS, AND CAPITAL EFFICIENCY HAMBURG, GERMANY / ACCESS NEWSWIRE / NOVEMBER 4, 2025 / EVOTEC SE (FRANKFURT STOCK EXCHANGE:EVT, SDAX/TECDAX, PRIME STANDARD, ISIN: DE0005664809, WKN 566480; NASDAQ:EVO), A LIFE SCIENCE COMPANY THAT IS PIONEERING THE FUTURE OF DRUG DISCOVERY AND DEVELOPMENT, TODAY ANNOUNCED THE SUCCESSFUL SIGNING OF THE SALE OF THE JUST - EVOTEC BIOLOGICS TOULOUSE SITE TO SANDOZ AG (SIX:SDZ)(OTCQX:SDZNY), A GLOBAL LEADER IN GENERIC AND BIOSIMILAR MEDICINES. UNDER THE LANDMARK TRANSACTION, SANDOZ WILL ACQUIRE 100% OF JUST - EVOTEC BIOLOGICS EU PLUS AN INDEFINITE TECHNOLOGY LICENSE TO EVOTEC'S CONTINUOUS MANUFACTURING PLATFORM TECHNOLOGY FOR A PAYMENT OF APPROXIMATELY US$ 350 M IN CASH.

IN A LANDMARK INDUSTRY TRANSACTION, EVOTEC SIGNS AGREEMENT WITH SANDOZ, RESULTING IN PAYMENTS POTENTIALLY OVER US $650 M PLUS ROYALTIES

HAMBURG, DE / ACCESS NEWSWIRE / OCTOBER 29, 2025 / EVOTEC SE (FRANKFURT STOCK EXCHANGE: EVT, SDAX/TECDAX, PRIME STANDARD, ISIN: DE0005664809, WKN 566480; NASDAQ:EVO) WILL ANNOUNCE ITS INTERIM STATEMENT FOR THE FIRST NINE MONTHS 2025 ON WEDNESDAY, 05 NOVEMBER 2025. THE COMPANY IS GOING TO HOLD A CONFERENCE CALL TO DISCUSS THE RESULTS AS WELL AS PROVIDE AN UPDATE ON ITS PERFORMANCE.

EVOTEC SE TO ANNOUNCE RESULTS FOR THE FIRST NINE MONTHS 2025 ON 05 NOVEMBER 2025

ADVANCES MADE IN PRECLINICAL PIPELINE ADDRESSING NEURODEGENERATIVE DISEASES EVOTEC RECEIVES US$ 25 M PAYMENT TO SUPPORT CONTINUED PROGRESSION OF JOINT PROGRAMS HAMBURG, DE / ACCESS NEWSWIRE / OCTOBER 27, 2025 / EVOTEC SE (FRANKFURT STOCK EXCHANGE: EVT, SDAX/TECDAX, PRIME STANDARD, ISIN: DE0005664809, WKN 566480; NASDAQ:EVO) TODAY ANNOUNCED THAT THE COMPANY HAS RECEIVED A PAYMENT OF US$ 25 M FROM BRISTOL MYERS SQUIBB (NYSE: BMY) FOR SCIENTIFIC PROGRESS ACHIEVED WITHIN THEIR STRATEGIC NEUROSCIENCE PARTNERSHIP. THE PAYMENT WILL ADVANCE FURTHER RESEARCH AND THE PARTNERS' JOINT PIPELINE OF PROGRAMS AIMED AT TACKLING NEUROGENERATIVE DISEASES.

Evotec SE

EVO

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Evotec SE

EVO.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

EVO